top of page
  • Warren RB, Smith RL, Campalani E, Eyre S, Smith CH, Barker JN, Worthington J, Griffiths CE. Outcomes of methotrexate therapy for psoriasis and relationship to genetic polymorphisms. Br J Dermatol. 2009 Feb;160(2):438-41

  • Warren RB, Smith RL, Campalani E, Eyre S, Smith CH, Barker JN, Worthington J, Griffiths CE. Genetic variation in efflux transporters influences outcome to methotrexate therapy in patients with psoriasis. J Invest Dermatol. 2008 Aug;128(8):1925-9

  • E Campalani, M Arenas, C Lewis, AM Marinaki, JNWN Barker, CH Smith. Polymorphisms in folate, pyrimidine and purine metabolic enzymes predict response to methotrexate in patients with chronic plaque psoriasis. J Invest Dermatol. 2007 Aug;127(8):1860-7

  • E Campalani, MH Allen, D Fairhurst, H Young, C Mendonca, DA Burden, CEM Griffiths, M Crook, JNWN Barker, CH Smith. Specific polymorphisms of the apolipoprotein E gene show association with chronic plaque and guttate psoriasis but do not have a role in disease response to acitretin treatment. Br J Dermatol. 2006 Feb;154(2):345-52

  • Young HS, Summers AM, Read IR, Fairhurst DA, Plant DJ, Campalani E, Smith CH, Barker JN, Detmar MJ, PEC Brenchley PE, Griffiths CE. Interaction between genetic control of vascular endothelial growth factor production and retinoid responsiveness in psoriasis. J Invest Dermatol. 2006 Feb;126(2):453-459

  • RA Palmer, CB van de Pas, E Campalani, SL Walker, AR Young, JLM Hawk. "A simple method to assess severity of polymorphic light eruption". Br J Dermatol. 2004 Sep;151(3):645-52

  • Ormerod AD, E Campalani, Goodfield MJ; BAD Clinical Standards Unit. British Association of Dermatologists guidelines on the efficacy and use of acitretin in dermatology. Br J Dermatol. 2010 May;162(5):952-63

  • E Campalani, SH Cliff. The management of acne scarring. MIMS 2010 March

  • E Campalani, JNWN Barker. The clinical genetics of psoriasis. Current genomics 2005 Feb;6(1):51-60

  • AP Cairns, SA Wright, JD Patton, E Campalani, AJ Taggart. "Rheumatology day care and the impact of biological therapies – the Belfast experience". Rheumatology (Oxford) 2002 Mar;41(3):356-7

Case Reports
  • F Worsnop, E Campalani. Paraneoplastic hypertrichosis lanuginosa acquisita: a delayed presentation in quiescent chronic lymphocytic leukaemia. Clin Exp Dermatol 2014 Jul;39(5):669-70

  • E Campalani, CAH Holden. Keratoacanthoma associated with the use of Imiquimod. Clin Exp Dermatol 2013 Jul;38(5):555-6. 

  • E Campalani, R Cerio, D Paige. A boy with persistent "atopic eczema" resistant to topical therapies. Clin Exp Dermatol. 2009 Dec;34(8):927-8

  • Walker SL, Lozewicz S, Sood R, Mann TA, Campalani E, Hubbard VG. Lupus vulgaris due to mycobacterium bovis bacillus Calmette-Guerin (BCG) at the site of previous BCG vaccination. Clin Exp Dermatol. 2009 Oct;34(7):e213-5

  • E Campalani, E Higgins. Erythema nodosum migrans. Clin Exp Dermatol 2003 Nov;28(6):679-80

  • E Campalani, GK Meenagh, MB Finch. An interesting case of Herpes Zoster in rheumatoid arthritis. Ann Rheum Dis 2002 Feb;61(2):102

bottom of page